WO1996011018A1 - Stable, aqueous alfa interferon solution formulations - Google Patents
Stable, aqueous alfa interferon solution formulationsInfo
- Publication number
- WO1996011018A1 WO1996011018A1 PCT/US1995/012362 US9512362W WO9611018A1 WO 1996011018 A1 WO1996011018 A1 WO 1996011018A1 US 9512362 W US9512362 W US 9512362W WO 9611018 A1 WO9611018 A1 WO 9611018A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alfa
- interferon
- formulation
- type interferon
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Definitions
- This invention relates to stable, aqueous solution formulations which are free of products derived from human blood serum and which maintain high biological activity and high chemical and high physical stability of alfa-type interferon for an extended period of time.
- U. S. Patent 4,496,537 discloses biologically stable alfa interferon aqueous solution formulations containing alfa interferon, human serum albumin and alanine or glycine, water, and a buffer system to maintain the pH at 6.5-8.0.
- the human serum albumin acts as a stabilizer for alfa interferon and prevents losses of alfa interferon from solution by coating and/or adsorption of the alfa interferon onto the stainless steel and glass surfaces of compounding vessels, process equipment and storage containers.
- Solution formulations containing alfa interferon and HSA have maintained the chemical and biological stability of the alfa interferon when such solutions have been stored at 2-8°C for extended periods, i.e., more than 2 years.
- the present invention provides a stable, aqueous solution formulation which maintains high biological alfa-type interferon activity and is free of human blood-derived products, which comprises:
- poly (oxy-1 ,2-ethanediyl) derivative sufficient to stabilize the alfa-type interferon against loss of alfa-type interferon; e. an effective amount of a tonicity agent; f. an effective amount of an antimicrobial preservative; and g. an amount of water for injection sufficient to prepare a solution of the above-listed ingredients.
- the present invention provides a stable, aqueous solution formulation having high alfa-type interferon biological activity and free of human blood-derived products, which comprises:
- a buffer system sufficient to maintain the pH of the solution in the range of 4.5 to 7.1 ;
- the present invention provides a stable, aqueous solution formulation having high biological alfa-type interferon activity and free of human blood-derived products, which comprises:
- the present invention further provides a stabile aqueous solution formulation having high biological alfa-type interferon activity and free of human blood-derived products, which comprises:
- the present invention also provides a process of preparing a stable, aqueous solution formulation having high biological alfa-type interferon activity and free of human blood-derived products comprising admixing an effective amount of alfa-type interferon with a buffer system capable of maintaining the pH within the range of 4.5 to 7.1 , a chelating agent, a sorbitan mono-9-octadecenoate poly(oxy-1 ,2-ethanediyl)derivative, a tonicity agent, an antimicrobial preservative and sufficient water to form a solution.
- the solution is prepared and maintained substantially free of dissolved oxygen and a headspace of inert atmosphere above the solution is maintained at a value of less than about 4% by volume of oxygen.
- high chemical stability as used herein in reference to the alfa-type interferon used in the formulations of the present invention means the alfa-type interferon maintains at least 85%, preferably 85% to 100% of its chemical integrity upon storage at 2° to 8°C for at least 24 months. See Tables 1 and 2. The chemical integrity is determined by measuring the protein content in an HPLC assay such as the one disclosed by T. L. Nagabhushan, et al., in an article entitled
- high biological stability as used herein in reference to the alfa-type interferon used in the formulations of the present invention means the alfa-type interferon in the formulation maintains at least 75%, preferably at least 85%, more preferably 90% to 100% of its biological activity upon storage at 2° to 8°C for at least 24 months (see results in Tables 1 to 4) as measured in the standard method of inhibition of the cytopathic effect (CPE) of a virus such as the method disclosed by W. P. Protzman, et al., in J. Clinical Microbiology, (1985), 22, 596-599.
- CPE cytopathic effect
- high physical stability as used herein in reference to the alfa-type interferon used in the formulations of the present invention means the formulation of the present invention remains clear, i.e., does not exhibit haze or visible particulate matter (i.e., particles greater than about 60 to 70 microns in diameter) on storage at 2° to 8°C for at least 24 months. See Tables 1, 2 and 3.
- the results listed in Tables 1 , 2 and 3 are surprising in that most solution formulations containing protein products like alfa-type interferon tend to develop visually observable particulate matter (i.e., particles having diameters greater than 60 to 70 microns) upon extended storage even at 2° to 8°C.
- the test method used to determine particulate matter in the solution formulation of this invention is described in The United States Pharmacopeia/The National Formulary USP 23/NF 18, published by United States
- a chelating agent included in the formulations of the present invention.
- suitable chelating agents include disodium dihydrogen ethylenediamine tetraacetate (EDTA or edetate disodium) or citric acid.
- EDTA disodium dihydrogen ethylenediamine tetraacetate
- edetate disodium is preferred. While we do not wish to be bound by any theory, it is believed that edetate disodium effectively complexes with trace amounts of metal cations, such as Zn 2+ , Fe 2+ , Cu 2+ or Al 3 +, which ions may be present in excipients and packaging components, e.g., rubber stoppers or gaskets.
- edetate disodium has a higher affinity for these metal cations than the alfa-type interferons, the interaction between metal cations and alfa-type interferon which results in formation of insoluble complexes (in the form of, for example, visible particulate matter) and loss of activity are avoided.
- the effective amount of the chelating agent is in the range of 0.01 to 1 mg/mL based on 0.1 ⁇ 10 6 to 100 ⁇ 10 6 International Units ("IU") of alfa-type interferon/mL
- 0.1 mg of edetate disodium is used for 5 ⁇ 10 6 to 50 ⁇ 10 6 IU of alfa-2 interferon.
- the buffer systems suitable for the formulations of the present invention are those which maintain the pH of the aqueous solution formulation in the range of 4.5 to 7.1 , preferably 6.5-7.1 and most preferably 6.8.
- the use of a buffer system of sodium phosphate dibasic and sodium phosphate monobasic is preferred. Normally a 0.005 to 0.1 molar buffer of the preferred sodium phosphate monobasic/dibasic buffer system is used for a formulation containing 0.1 ⁇ 10 6 to 100 ⁇ 10 6 IU of alfa-type interferon per mL.
- Other suitable buffer systems to maintain the desired pH range of 4.5 to 7.1 include sodium citrate/citric acid and sodium acetate/acetic acid.
- the tonicity agent useful in the present invention is any agent capable of rendering the formulations of the present invention iso-osmotic with human serum.
- suitable tonicity agents include sodium chloride, mannitol, glycine, glucose and sorbitol. Use of sodium chloride as a tonicity agent is preferred.
- the amount of the tonicity agent used is in the range of 1 to 10 mg/mL when the formulation of the present invention contains 0.1 ⁇ 10 6 to 100 ⁇ 10 6 IU of alfa-type interferon/mL.
- the use of 7.5 mg/mL of sodium chloride is preferred for 5 ⁇ 10 6 to 50 ⁇ 10 6 IU of alfa-type interferon per mL in the formulations of the present invention.
- the sorbitan mono-9-octadecenoate poly(oxy-1,2-ethanediyl) derivatives such as polysorbate 80 or polysorbate 20 are useful as a stabilizing agent to prevent adsorption of the alfa-type interferon proteins such as alfa-2b interferon onto the stainless steel and glass surfaces of the equipment used to make the indictable formulations containing alfa-type interferon.
- the amount of polysorbate 20 or 80 effective in the formulation of this invention is in the range of 0.01 to 1.0 mg per mL for a formulation containing 0.1 ⁇ 10 6 to 100 ⁇ 10 6 IU of alfa-type interferon per mL.
- the use of polysorbate 80 is preferred.
- polysorbate 80 is more preferred in all the solution formulations of the present invention.
- concentrations of alfa-type interferon such as alfa-2 interferon is less than about 15 ⁇ 10 6 lU/mL, e.g., 6 ⁇ 10 6 lU/mL
- loss of activity due to adsorption of the alfa interferon in the absence of polysorbate 80 significantly lowers the biological activity of the formulation.
- polysorbate 80 prevents loss of alfa-2b interferon and allows systemic delivery of the alfa-2b interferon without loss of biological activity.
- polysorbate 80 provided superior chemical and biological stability to alfa-2b interferon compared to other non-ionic surfactants, e.g., Pluronic F127 and Pluronic F-68.
- alfa-type interferon useful in the formulation of the present invention is in the range of 0,1 ⁇ 10 6 to 100 ⁇ 10 6 lU/mL, preferably 5 ⁇ 10 6 to 50 ⁇ 10 6 IU/mL
- alfa-type interferon means the family of highly homologous species-specific proteins that inhibit viral replication and cellular proliferation and modulate immune response.
- suitable alfa-type interferons include interferon alfa-2a such as ROFERON A interferon alfa-2a available from Hoffmann-La Roche, Nutley, N.J., interferon alfa-2b such as INTRON A interferon alfa-2b available from Schering Corporation, Kenilworth, NJ.
- interferon alfa-2c such as BEROFOR interferon alfa-2c available from Boehringer Ingelheim Pharmaceutical, Inc., Ridgefield, CT., interferon alfa-n1, a purified blend of natural alfa interferons such as SUMIFERON available from Sumitomo, Japan or as WELLFERON interferon alfa-n1 available from The Wellcome Foundation Ltd., London, Great Britain, or consensus alfa interferon available from Am gen, Inc., Newbury Park, California, or interferon alfa-n3, a mixture of natural alfa interferons, made by Interferon Sciences and available from the Purdue Frederick Co., Norwalk, CT., under the ALFERON tradename.
- interferon alfa-2a or alfa-2b is preferred.
- the use of interferon alfa-2b is more preferred.
- the antimicrobial preservatives found useful in the present invention include m-cresol, phenol and methyl- paraben and propylparaben and mixtures of the above-listed preservatives, e.g., phenol-methylparaben mixtures.
- the effective amount of m-cresol found useful in the present invention is in the range of 0.5 to 2 mg/mL for a formulation containing 0.1 ⁇ 10 6 to 100 ⁇ 10 6 lU/mL of alfa-type interferon. It is preferred to use 1.5 mg/mL of m-cresol for a formulation containing 5 ⁇ 10 6 to 50 ⁇ 10 6 lU/mL of interferon alfa-2b.
- the effective amount of phenol found useful is in the range of 0.5 to 5 mg/mL for a solution formulation containing 0.1 ⁇ 10 6 to 100 ⁇ 10 6 lU/mL of alfa-type interferon.
- the effective amount of methylparaben is in the range of 0.6 to 1.8 mg/mL and the amount of propylparaben is in the range of 0.06 to 0.18 mg/mL when the formulation of the present invention contains 0.1 ⁇ 10 6 to 100 ⁇ 10 6 lU/mL of alfa-type interferon. It is preferred to use 1.2 mg/mL of methylparaben in combination with
- the water used for preparation of the formulations of the present invention is preferably water for injection.
- antimicrobial preservative which could be added to the aqueous solution formulation to provide the appropriate antimicrobial protection for said formulation pursuant to various worldwide health registration requirements without causing undesirable haze formation in the solution.
- the effective amount of the preferred antimicrobial preservative e.g., m-cresol which could be added without causing hazing of said formulation was found to be critical. For example if the amount of m-cresol added to a
- the effective amount of methylparaben should be no more than about 1.2 mg/mL when used with 0.12 mg/mL of propylparaben to avoid hazing, and the effective amount of phenol (when it is used in place of the parabens) should be in the range of 0.5 to less than about 4 mg/mL to avoid hazing.
- Alfa-type interferon formulations are useful for treatment of a variety of disease states such as renal cell carcinomas, AIDS-related Kaposi's sarcoma, chronic and acute hepatitis B, chronic and acute non-A, non-B/C hepatitis.
- the formulations of the present invention are useful in treating these disease states preferably as injectable aqueous solutions.
- Example 5 The procedures listed after Example 5 are used to prepare the formulations of the present invention of Examples 1 to 5.
- Example 4 The formulation of Example 3 was prepared with 6 ⁇ 10 6 lU/mL of alfa-2b interferon in accordance with the method of manufacture detailed herein below using nitrogen sparging of the solution and maintaining no more than about 4% by volume of oxygen in the headspace. Vials containing a label volume of 3 mL of solution were stored at 30°, 25° and 4°C. The results are summarized in Table 3.
- Example 4 The formulation of Example 4 was prepared in accordance with the method of manufacture detailed hereinbelow in all details except no nitrogen was sparged through the solution or overlaid upon it and the oxygen volume in the headspace was ⁇ 20% by volume as found in ambient air.
- Vials containing a label volume of 3 mL of solution were stored at 30°, 25° and 4°C. The results are summarized in Table 4.
- step 4 Cool the solution in step 3 to a temperature between 20° and 25°C. Sparge and overlay the solution with filtered nitrogen. Maintain a dissolved oxygen level at or below 0.25 ppm.
- step 2 Add water for injection that has been sparged with nitrogen (from step 2) to bring batch to final volume. Agitate solution gently until homogeneous.
- Example 3 is exactly the same as described hereinabove except the temperature of the solution in Step 3 is maintained between 20° and 25°C and the m-cresol is charged after Step 6.
- the water used to prepare the aqueous alfa interferon solution as well as the so-formed aqueous alfa interferon solution be substantially free of dissolved oxygen, and the aqueous solution be made and stored with a headspace of an inert atmosphere, such as nitrogen, containing no more than about 4% volume of oxygen.
- substantially free of dissolved oxygen as used herein is meant an oxygen level of no more than about 0.25 ppm at a water temperature of about 20° - 25°C. Normally, this preferred dissolved oxygen level of 0.25 ppm is conveniently achieved by sparging an inert atmosphere, e.g.
- aqueous formulations of the present invention which have a dissolved oxygen level of 1ppm and an oxygen content in the headspace of 7% by volume demonstrated significantly greater loss of chemical stability of the alfa interferon after 3 months of storage at 25°C compared to a similar aqueous formulation having the preferred dissolved oxygen level of 0.25 ppm and an oxygen content in the headspace of 4% by volume stored under the same conditions.
- the aqueous solution formulation of the present invention may be stored in any suitable washed and sterilized filing vessels or container such as 2-mL or 5-mL Type I flint glass vials stoppered with gray butyl rubber closures.
- the aqueous solution formulations of the present invention may also be stored in prefilled multi-dose syringes such as those useful for delivery of indictable solutions of drugs such as insulin.
- Typical suitable syringes include systems comprising a prefilled vial attached to a pen-type syringe such as the Novolet Novo Pen available from Novo Nordisk.
- Typical suitable systems include a prefilled, pen-type syringe which allows easy self-injection by the user as well as accurate, reproducible dose settings.
- aqueous solutions formulations of the present invention may also be lyophiiized to form a powder for reconstitution.
- the lyophiiized alfa-type interferon powder is expected to maintain its chemical and biological stability when stored at 2° to 8°C for at least 2 years.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SK439-97A SK282949B6 (en) | 1994-10-11 | 1995-10-10 | Stable, aqueous alpha interferon solution formulations |
CZ0110497A CZ296961B6 (en) | 1994-10-11 | 1995-10-10 | Stable, aqueous injectable formulation having high biological alpha-type interferon activity, article containing thereof and process for its preparation |
DE69518084T DE69518084T2 (en) | 1994-10-11 | 1995-10-10 | STABLE, AQUEOUS ALPHA INTERFERON SOLUTIONS |
JP51260696A JP3978228B2 (en) | 1994-10-11 | 1995-10-10 | Stable, aqueous alpha interferon solution formulation |
BR9509313A BR9509313A (en) | 1994-10-11 | 1995-10-10 | Formulations of stable aqueous solutions of alpha interferon |
UA97052124A UA42028C2 (en) | 1994-10-11 | 1995-10-10 | Preparation of alpha interferon in form of stable aqueous solution |
AU37279/95A AU708337B2 (en) | 1994-10-11 | 1995-10-10 | Stable, aqueous alfa interferon solution formulations |
CA002201749A CA2201749C (en) | 1994-10-11 | 1995-10-10 | Stable aqueous alfa interferon solution formulations |
AT95935151T ATE194774T1 (en) | 1994-10-11 | 1995-10-10 | STABLE, AQUEOUS ALPHA INTERFERON SOLUTIONS |
EP95935151A EP0777495B1 (en) | 1994-10-11 | 1995-10-10 | Stable, aqueous alfa interferon solution formulations |
EP99119434A EP0970703B1 (en) | 1994-10-11 | 1995-10-10 | Use of metal chelating agents to stabilize preparations containing interferon |
DK95935151T DK0777495T3 (en) | 1994-10-11 | 1995-10-10 | Stable aqueous alpha-interferon solution formulations |
HU9702262A HU225494B1 (en) | 1994-10-11 | 1995-10-10 | Stable, aqueous alfa interferon solution formulations |
PL95319603A PL183797B1 (en) | 1994-10-11 | 1995-10-10 | Stable aqueous alpha interferon preparations |
NZ294464A NZ294464A (en) | 1994-10-11 | 1995-10-10 | Stable, aqueous formulation having high biological alpha-type interferon activity buffered from 4.5 to 7.1 and comprising chelating agent and a polyoxyethylene sorbitan monooleate, formulation free from human blood-derived products |
MXPA/A/1997/002578A MXPA97002578A (en) | 1994-10-11 | 1997-04-09 | Alfa-interferonestable acu solution formulations |
NO19971633A NO320604B1 (en) | 1994-10-11 | 1997-04-10 | Stable aqueous alpha interferon solution formulations |
FI971486A FI116558B (en) | 1994-10-11 | 1997-04-10 | Stable aqueous solution formulations of interferon alpha |
HK98109513A HK1008813A1 (en) | 1994-10-11 | 1998-07-29 | Stable aqueous alfa interferon solution formulations |
GR20000402304T GR3034619T3 (en) | 1994-10-11 | 2000-10-13 | Stable, aqueous alfa interferon solution formulations |
FI20055562A FI117377B (en) | 1994-10-11 | 2005-10-19 | Use of chelating agent in stable aqueous formulations containing alpha-type interferon |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/329,813 | 1994-10-11 | ||
US08/329,813 US5766582A (en) | 1994-10-11 | 1994-10-11 | Stable, aqueous alfa interferon solution formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996011018A1 true WO1996011018A1 (en) | 1996-04-18 |
Family
ID=23287133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/012362 WO1996011018A1 (en) | 1994-10-11 | 1995-10-10 | Stable, aqueous alfa interferon solution formulations |
Country Status (25)
Country | Link |
---|---|
US (2) | US5766582A (en) |
EP (2) | EP0777495B1 (en) |
JP (2) | JP3978228B2 (en) |
KR (1) | KR100401401B1 (en) |
CN (1) | CN1102408C (en) |
AT (2) | ATE194774T1 (en) |
AU (1) | AU708337B2 (en) |
BR (1) | BR9509313A (en) |
CA (1) | CA2201749C (en) |
CZ (1) | CZ296961B6 (en) |
DE (2) | DE69518084T2 (en) |
DK (1) | DK0777495T3 (en) |
ES (2) | ES2148568T3 (en) |
FI (2) | FI116558B (en) |
GR (1) | GR3034619T3 (en) |
HK (1) | HK1008813A1 (en) |
HU (1) | HU225494B1 (en) |
NO (1) | NO320604B1 (en) |
NZ (1) | NZ294464A (en) |
PL (1) | PL183797B1 (en) |
PT (1) | PT777495E (en) |
RU (1) | RU2157236C2 (en) |
SK (1) | SK282949B6 (en) |
UA (1) | UA42028C2 (en) |
WO (1) | WO1996011018A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999048535A1 (en) * | 1998-03-26 | 1999-09-30 | Schering Corporation | Formulations for protection of peg-interferon alpha conjugates |
US6180096B1 (en) | 1998-03-26 | 2001-01-30 | Schering Corporation | Formulations for protection of peg-interferon alpha conjugates |
WO2001035987A1 (en) * | 1999-11-19 | 2001-05-25 | Lg Chem Investment, Ltd. | An aqueous solution formulation of alpha-interferon |
WO2001044441A1 (en) * | 1999-12-14 | 2001-06-21 | Thermo Biostar, Inc. | Stabilizing diluent for polypeptides and antigens |
EP1250932A1 (en) * | 1999-12-06 | 2002-10-23 | Tianjin Hualida Bioengineering Co. Ltd. | A stable aqua formulation of interferon, the preparation method and the uses thereof |
WO2002083165A1 (en) * | 2001-04-10 | 2002-10-24 | Sumitomo Pharmaceuticals Co., Ltd. | Stable preparations for injection |
US7632491B2 (en) | 2004-08-12 | 2009-12-15 | Schering Corporation | Stable pegylated interferon formulation |
US8512692B2 (en) | 1996-12-24 | 2013-08-20 | Biogen Idec Ma Inc. | Methods of treating multiple sclerosis with stable liquid interferon-beta formulations |
US9669105B2 (en) | 2010-10-26 | 2017-06-06 | Hanmi Science Co., Ltd. | Liquid formulations of long-acting interferon alpha conjugates |
RU2768656C1 (en) * | 2021-09-10 | 2022-03-24 | Илья Александрович Марков | Antiviral agent in liquid form and method for its preparation |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ300540B6 (en) | 1998-05-15 | 2009-06-10 | Schering Corporation | Pharmaceutical composition comprising ribavirin combined with alpha interferon for treating patients with chronic infection of hepatitis C of genotype 1 |
EP1129111B1 (en) | 1998-11-12 | 2008-10-01 | Schering Corporation | Methods for conversion of interferon isoforms and products thereof |
US6281337B1 (en) | 1998-11-12 | 2001-08-28 | Schering Corporation | Methods for conversion of protein isoforms |
US7402559B2 (en) * | 1999-03-24 | 2008-07-22 | Msh Pharma, Incorporated | Composition and method of treatment for urogenital conditions |
US6362162B1 (en) | 1999-04-08 | 2002-03-26 | Schering Corporation | CML Therapy |
US6923966B2 (en) | 1999-04-08 | 2005-08-02 | Schering Corporation | Melanoma therapy |
CN1390132A (en) | 1999-04-08 | 2003-01-08 | 先灵公司 | Use of pegylated interferon alpha in melanoma therapy |
US6605273B2 (en) | 1999-04-08 | 2003-08-12 | Schering Corporation | Renal cell carcinoma treatment |
AR029160A1 (en) * | 1999-04-08 | 2003-06-18 | Schering Corp | THE USE OF PEGILATED INTERFERON-ALFA FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF RENAL CELL CARCINOMA, A KIT AND THE USE OF IT |
CA2369444C (en) * | 1999-04-09 | 2009-08-18 | Ortho-Mcneil Pharmaceutical, Inc. | Pharmaceutical compositions of erythropoietin |
JP4536194B2 (en) * | 2000-02-17 | 2010-09-01 | 大日本住友製薬株式会社 | Stable injectable formulation |
CN1245215C (en) | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | Recombinant super-compound interferon used as hepatitis B surface antigen and e antigen inhibitor |
JP4320177B2 (en) * | 2001-04-04 | 2009-08-26 | アルザ・コーポレーシヨン | Transdermal electrotransport delivery device comprising an antimicrobial compatible reservoir composition |
LT4947B (en) | 2001-09-26 | 2002-08-26 | Biotechnologijos Institutas | Alfa interferon pharmaceutical composition |
US20050232899A1 (en) * | 2002-05-31 | 2005-10-20 | Aradigm Corporation | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
US6830744B2 (en) * | 2002-05-31 | 2004-12-14 | Aradigm Corporation | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
US7148211B2 (en) * | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
US20040058895A1 (en) * | 2002-09-18 | 2004-03-25 | Bone Care International, Inc. | Multi-use vessels for vitamin D formulations |
US20040053895A1 (en) * | 2002-09-18 | 2004-03-18 | Bone Care International, Inc. | Multi-use vessels for vitamin D formulations |
US20040175359A1 (en) * | 2002-11-12 | 2004-09-09 | Desjarlais John Rudolph | Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity |
US7585647B2 (en) | 2003-08-28 | 2009-09-08 | Guangwen Wei | Nucleic acid encoding recombinant interferon |
GB2429207A (en) * | 2004-02-02 | 2007-02-21 | Ambrx Inc | Modified human interferon polypeptides and their uses |
CN1724567B (en) * | 2004-07-22 | 2010-08-18 | 北京三元基因工程有限公司 | Stable recombination human interferon alpha 1b water solution |
US20060204474A1 (en) * | 2005-02-25 | 2006-09-14 | Coroneo Minas T | Treatment of epithelial layer lesions |
ES2302402B1 (en) | 2005-06-16 | 2009-05-08 | Proyecto De Biomedicina Cima, S.L. | USE OF A CYTOQUINE OF THE INTERLEUQUINA-6 FAMILY IN THE PREPARATION OF A COMPOSITION FOR ADMINISTRATION COMBINED WITH INTERFERON-ALFA. |
CU23432B6 (en) * | 2005-11-02 | 2009-10-16 | Ct Ingenieria Genetica Biotech | STABILIZED FORMULATIONS CONTAINING GAMMA AND ALFA INTERFERONS IN POTENTIAL PROPORTIONS |
US8679472B1 (en) | 2006-10-05 | 2014-03-25 | Merck, Sharp & Dohme Corp. | Crystal of human interferon alpha 2B in complex with zinc |
CN103965347B (en) | 2007-05-02 | 2017-07-18 | Ambrx公司 | Modified interferon beta polypeptides and its purposes |
US8216571B2 (en) * | 2007-10-22 | 2012-07-10 | Schering Corporation | Fully human anti-VEGF antibodies and methods of using |
EP2286359A2 (en) * | 2008-03-27 | 2011-02-23 | Medtronic, Inc. | Method and system to define patient specific therapeutic regimens by means of pharmacokinetic and pharmacodynamic tools |
US20110293557A1 (en) | 2008-06-13 | 2011-12-01 | Proyecto De Biomedicina Cima, S.L. | Conjugates for the administration of biologically active compounds |
KR101820024B1 (en) | 2008-10-17 | 2018-01-18 | 사노피-아벤티스 도이칠란트 게엠베하 | Combination of an insulin and a GLP-1 agonist |
RU2014102102A (en) | 2011-06-23 | 2015-07-27 | Дигна Байотек, С.Л. | COMPOSITION AND COMBINED DRUG INTERFERON-a5 WITH INTERFERON-a2 AND METHOD OF TREATMENT OF CHRONIC HEPATITIS C |
EA201590790A1 (en) | 2012-10-26 | 2015-08-31 | Люпин Лимитед | STABLE PHARMACEUTICAL COMPOSITION BASED ON PEG-INTERFERON ALPHA-2b |
DK2983697T3 (en) | 2013-04-03 | 2019-02-25 | Sanofi Sa | TREATMENT OF DIABETES MELLITUS WITH LONG-EFFECTIVE FORMULATIONS OF INSULIN |
US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
ES2524516B1 (en) * | 2014-05-29 | 2015-03-31 | Grifols Worldwide Operations Limited | Preparation procedure of human albumin with reduced dissolved oxygen level |
WO2016046101A1 (en) * | 2014-09-23 | 2016-03-31 | F. Hoffmann-La Roche Ag | Stable, benzyl alcohol-free aqueous solution formulations containing alpha-type interferon |
TWI748945B (en) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | Treatment type 2 diabetes mellitus patients |
TW201705975A (en) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | Treatment of type 2 diabetes mellitus patients |
MA45276A (en) * | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE |
RU2623050C2 (en) * | 2015-12-03 | 2017-06-21 | Виталий Эдуардович Боровиков | Chondroitin sulfate solution for intramuscular administration and method for its preparation |
KR200492470Y1 (en) | 2020-03-26 | 2020-10-21 | 사공탁 | Villa housing garbage collection box |
CN113797318B (en) * | 2021-10-26 | 2023-06-30 | 深圳科兴药业有限公司 | Interferon composition and preparation method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59176216A (en) * | 1983-03-28 | 1984-10-05 | Sumitomo Chem Co Ltd | Useful pharmaceutical preparation of interferon |
JPS61277633A (en) * | 1985-05-31 | 1986-12-08 | Toray Ind Inc | Interferon composition |
EP0284249A1 (en) * | 1987-03-13 | 1988-09-28 | Interferon Sciences, Inc. | Lyophilized lymphokine composition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3262575D1 (en) * | 1981-12-23 | 1985-04-18 | Schering Corp | Stabilised interferon formulations and their preparation |
US4680175A (en) * | 1984-02-07 | 1987-07-14 | Interferon Sciences, Inc. | Interferon administration vehicles |
JPS60243028A (en) * | 1984-04-28 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | Solubilization of interferon |
US4857316A (en) * | 1984-10-03 | 1989-08-15 | Syntex (U.S.A.) Inc. | Synergistic antiviral composition |
US4606917A (en) * | 1984-10-03 | 1986-08-19 | Syntex (U.S.A) Inc. | Synergistic antiviral composition |
US4847079A (en) * | 1985-07-29 | 1989-07-11 | Schering Corporation | Biologically stable interferon compositions comprising thimerosal |
US5266310A (en) * | 1987-09-17 | 1993-11-30 | Boehringer Ingelheim International Gmbh | Stabilization of therapeutically active proteins in pharmaceutical preparations |
IL88233A (en) * | 1987-11-03 | 1993-08-18 | Genentech Inc | Gamma interferon formulation |
DE4126983A1 (en) * | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | METHOD FOR THE PRODUCTION OF HUMAN-PROTEIN-CONTAINING, PRESERVED MEDICAMENTS FOR INFUSION OR INJECTION USE |
JP3292894B2 (en) * | 1993-05-12 | 2002-06-17 | 日本電信電話株式会社 | Integrated light receiving circuit |
-
1994
- 1994-10-11 US US08/329,813 patent/US5766582A/en not_active Expired - Lifetime
-
1995
- 1995-10-10 DE DE69518084T patent/DE69518084T2/en not_active Expired - Lifetime
- 1995-10-10 JP JP51260696A patent/JP3978228B2/en not_active Expired - Lifetime
- 1995-10-10 PL PL95319603A patent/PL183797B1/en unknown
- 1995-10-10 AT AT95935151T patent/ATE194774T1/en active
- 1995-10-10 HU HU9702262A patent/HU225494B1/en unknown
- 1995-10-10 AU AU37279/95A patent/AU708337B2/en not_active Expired
- 1995-10-10 CN CN95195600A patent/CN1102408C/en not_active Expired - Lifetime
- 1995-10-10 CZ CZ0110497A patent/CZ296961B6/en not_active IP Right Cessation
- 1995-10-10 PT PT95935151T patent/PT777495E/en unknown
- 1995-10-10 CA CA002201749A patent/CA2201749C/en not_active Expired - Lifetime
- 1995-10-10 SK SK439-97A patent/SK282949B6/en not_active IP Right Cessation
- 1995-10-10 UA UA97052124A patent/UA42028C2/en unknown
- 1995-10-10 EP EP95935151A patent/EP0777495B1/en not_active Expired - Lifetime
- 1995-10-10 BR BR9509313A patent/BR9509313A/en not_active IP Right Cessation
- 1995-10-10 NZ NZ294464A patent/NZ294464A/en not_active IP Right Cessation
- 1995-10-10 DK DK95935151T patent/DK0777495T3/en active
- 1995-10-10 ES ES95935151T patent/ES2148568T3/en not_active Expired - Lifetime
- 1995-10-10 RU RU97107611/14A patent/RU2157236C2/en active
- 1995-10-10 WO PCT/US1995/012362 patent/WO1996011018A1/en active IP Right Grant
- 1995-10-10 DE DE69531314T patent/DE69531314T2/en not_active Expired - Lifetime
- 1995-10-10 ES ES99119434T patent/ES2198830T3/en not_active Expired - Lifetime
- 1995-10-10 KR KR1019970702346A patent/KR100401401B1/en not_active IP Right Cessation
- 1995-10-10 EP EP99119434A patent/EP0970703B1/en not_active Expired - Lifetime
- 1995-10-10 AT AT99119434T patent/ATE245033T1/en not_active IP Right Cessation
-
1997
- 1997-04-10 FI FI971486A patent/FI116558B/en not_active IP Right Cessation
- 1997-04-10 NO NO19971633A patent/NO320604B1/en not_active IP Right Cessation
-
1998
- 1998-06-12 US US09/096,708 patent/US5935566A/en not_active Expired - Lifetime
- 1998-07-29 HK HK98109513A patent/HK1008813A1/en not_active IP Right Cessation
-
2000
- 2000-10-13 GR GR20000402304T patent/GR3034619T3/en unknown
-
2005
- 2005-10-19 FI FI20055562A patent/FI117377B/en not_active IP Right Cessation
-
2006
- 2006-04-20 JP JP2006117296A patent/JP2006193536A/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59176216A (en) * | 1983-03-28 | 1984-10-05 | Sumitomo Chem Co Ltd | Useful pharmaceutical preparation of interferon |
JPS61277633A (en) * | 1985-05-31 | 1986-12-08 | Toray Ind Inc | Interferon composition |
EP0284249A1 (en) * | 1987-03-13 | 1988-09-28 | Interferon Sciences, Inc. | Lyophilized lymphokine composition |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Section Ch Week 8446, Derwent World Patents Index; Class B04, AN 84-285358 * |
DATABASE WPI Section Ch Week 8703, Derwent World Patents Index; Class B04, AN 87-018978 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8512692B2 (en) | 1996-12-24 | 2013-08-20 | Biogen Idec Ma Inc. | Methods of treating multiple sclerosis with stable liquid interferon-beta formulations |
US9522174B2 (en) | 1996-12-24 | 2016-12-20 | Biogen Ma Inc. | Stable liquid interferon beta formulations |
US8932574B2 (en) | 1996-12-24 | 2015-01-13 | Biogen Idec Ma Inc. | Stable liquid interferon beta formulations |
US8512691B2 (en) | 1996-12-24 | 2013-08-20 | Biogen Idec Ma Inc. | Stable liquid interferon-beta formulations |
US6180096B1 (en) | 1998-03-26 | 2001-01-30 | Schering Corporation | Formulations for protection of peg-interferon alpha conjugates |
AU754002B2 (en) * | 1998-03-26 | 2002-10-31 | Merck Sharp & Dohme Corp. | Formulations for protection of peg-interferon alpha conjugates |
KR100420642B1 (en) * | 1998-03-26 | 2004-03-02 | 쉐링 코포레이션 | Formulations for protection of peg-interferon alpha conjugates |
WO1999048535A1 (en) * | 1998-03-26 | 1999-09-30 | Schering Corporation | Formulations for protection of peg-interferon alpha conjugates |
WO2001035987A1 (en) * | 1999-11-19 | 2001-05-25 | Lg Chem Investment, Ltd. | An aqueous solution formulation of alpha-interferon |
AU777994B2 (en) * | 1999-11-19 | 2004-11-11 | Lg Chem Investment Ltd. | An aqueous solution formulation of alpha-interferon |
EP1250932A1 (en) * | 1999-12-06 | 2002-10-23 | Tianjin Hualida Bioengineering Co. Ltd. | A stable aqua formulation of interferon, the preparation method and the uses thereof |
EP1250932A4 (en) * | 1999-12-06 | 2006-04-19 | Tianjin Hualida Biotechnology | A stable aqua formulation of interferon, the preparation method and the uses thereof |
AU783246B2 (en) * | 1999-12-14 | 2005-10-06 | Asahi Kasei Kabushiki Kaisha | Stabilizing diluent for polypeptides and antigens |
KR100771294B1 (en) * | 1999-12-14 | 2007-10-29 | 써모 바이오스타, 인크. | Stabilizing diluent for polypeptides and antigens |
AU783246C (en) * | 1999-12-14 | 2007-03-15 | Asahi Kasei Kabushiki Kaisha | Stabilizing diluent for polypeptides and antigens |
US6579688B2 (en) | 1999-12-14 | 2003-06-17 | Biostar, Inc. | Stabilizing diluent for polypeptides and antigens |
WO2001044441A1 (en) * | 1999-12-14 | 2001-06-21 | Thermo Biostar, Inc. | Stabilizing diluent for polypeptides and antigens |
WO2002083165A1 (en) * | 2001-04-10 | 2002-10-24 | Sumitomo Pharmaceuticals Co., Ltd. | Stable preparations for injection |
US7632491B2 (en) | 2004-08-12 | 2009-12-15 | Schering Corporation | Stable pegylated interferon formulation |
US9669105B2 (en) | 2010-10-26 | 2017-06-06 | Hanmi Science Co., Ltd. | Liquid formulations of long-acting interferon alpha conjugates |
RU2768656C1 (en) * | 2021-09-10 | 2022-03-24 | Илья Александрович Марков | Antiviral agent in liquid form and method for its preparation |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0970703B1 (en) | Use of metal chelating agents to stabilize preparations containing interferon | |
AU686567C (en) | Human growth hormone aqueous formulation | |
US5981485A (en) | Human growth hormone aqueous formulation | |
US5763394A (en) | Human growth hormone aqueous formulation | |
EP1066059B1 (en) | Formulations for protection of peg-interferon alpha conjugates | |
CA2521560A1 (en) | Hsa-free stabilized interferon liquid formulations | |
MXPA97002578A (en) | Alfa-interferonestable acu solution formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95195600.0 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995935151 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 294464 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2201749 Country of ref document: CA Ref document number: 2201749 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 43997 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/002578 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1997-1104 Country of ref document: CZ Ref document number: 971486 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970702346 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1995935151 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1997-1104 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970702346 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995935151 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019970702346 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20055562 Country of ref document: FI |
|
WWG | Wipo information: grant in national office |
Ref document number: 971486 Country of ref document: FI |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1997-1104 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 20055562 Country of ref document: FI |